Synribo (Omacetaxine Mepesuccinate) For Myelogenous Leukemia, Approved By FDA
10/29/2012
Synribo (omacetaxine mepesuccinate) has been approved by the FDA (US Food and Drug Administration) for the treatment of chronic myelogenous leukemia (CML) in adult patients. Chronic myelogenous leukemia is also known as chronic myeloid leukemia. Approximately 5,430 are expected to be diagnosed with CML, a blood and bone marrow disease, in 2012, says the NIH (National Institutes of Health)...
Cheap, Ultra-Sensitive Colour Test Spots Early HIV, Cancer
10/29/2012
Researchers in the UK have developed a "naked eye" colour test for virus and disease biomarkers that is ten times more sensitive than current gold standard methods. They have tested it on HIV and prostate cancer biomarkers, and suggest it offers a cheap and simple way of spotting early onset of these and other diseases that could be of particular benefit in poorer countries...
Prostate Cancer Recurrence More Likely When Testosterone Drops After Radiation
10/29/2012
Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center. The findings will be presented on October 29 at the American Society for Radiation Oncology's 54th Annual Meeting...
Genetic Mutations Tested In Zebrafish
10/29/2012
The zebrafish is a potential tool for testing one class of unique individual genetic differences found in humans, and may yield information helpful for the emerging field of personalized medicine, according to a team led by Penn State College of Medicine scientists...
Spread Of Rectal Cancer To Lymph Nodes More Likely At Younger Age
10/29/2012
Rectal cancer is more likely to spread to the lymph nodes in younger patients, according to new findings that Fox Chase Cancer Center researchers will be presenting on October 29 at the American Society for Radiation Oncology's 54th Annual Meeting. The results - which are the first of their kind - suggest that doctors should search for spreading more aggressively in these patients...
Multifocal/Multicentric Breast Cancer Connected To A Patient's Risk Of Local Recurrence
10/29/2012
Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy...
Intracoronary And Intravenous Use Of Abciximab During Angioplasty Yield Similar Results
10/29/2012
Results of the AIDA STEMI MRI sub-study presented at TCT 2012 A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV)...
Synribo (Omacetaxine Mepesuccinate) For Myelogenous Leukemia, Approved By FDA
10/29/2012
Synribo (omacetaxine mepesuccinate) has been approved by the FDA (US Food and Drug Administration) for the treatment of chronic myelogenous leukemia (CML) in adult patients. Chronic myelogenous leukemia is also known as chronic myeloid leukemia. Approximately 5,430 are expected to be diagnosed with CML, a blood and bone marrow disease, in 2012, says the NIH (National Institutes of Health)...
Key Regulatory Pathways Of Myeloid Differentiation Identified
10/29/2012
Associate Professor of Cell and Developmental Biology Fei Wang and colleagues have created a new technique to study how myeloids, a type of blood stem cell, become the white blood cells important for immune system defense against infections and tissue damage...
When astronauts return to Earth, their altitude isn't the only thing that drops - their blood pressure does too. This condition, known as orthostatic hypotension, occurs in up to half of those astronauts on short-term missions (two weeks or less) and in nearly all astronauts after long-term missions (four to six months)...